Form 4: PLUS THERAPEUTICS CEO Marc Hedrick's RSU Vesting

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

Summary

• Marc H. Hedrick, Chief Executive Officer and Director of PLUS THERAPEUTICS, INC. (PSTV), reported a change in beneficial ownership.
• On January 1, 2026, 159,681 Restricted Stock Units (RSUs) vested and converted into an equal number of common stock shares.
• Each RSU represents a contingent right to receive one share of the issuer's Common Stock at a price of $0.
• Following this transaction, Mr. Hedrick directly beneficially owns 339,787 shares of Common Stock.
• He also directly beneficially owns 1,596,806 derivative securities in the form of Restricted Stock Units.
• The RSU grant vests in twelve substantially equal quarterly installments, commencing on October 1, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine vesting of executive compensation, which is a neutral to slightly positive event as it aligns management's interests with shareholders. No significant positive or negative operational news is present.

Positives

• Vesting of 159,681 Restricted Stock Units (RSUs) for CEO Marc H. Hedrick, aligning management and shareholder interests.
• The transaction represents a routine compensation event, indicating ongoing executive retention and motivation.

Future Outlook

The remaining 1,596,806 Restricted Stock Units held by Marc H. Hedrick are expected to vest in future quarterly installments, continuing the alignment of executive compensation with company performance.

Industry Context

This is a standard insider transaction disclosure for executive compensation, common across all publicly traded industries, reflecting a company's compensation structure for its leadership.

Related Party Transactions

• The vesting of Restricted Stock Units and subsequent acquisition of common stock by CEO Marc H. Hedrick is a transaction between a related party (executive) and the issuer, consistent with his compensation agreement.

Stakeholder Impact

• Shareholders: Increased direct beneficial ownership by the CEO may signal confidence and further align his interests with shareholder value creation.
• Employees: Routine executive compensation events can contribute to overall employee morale and perception of fair compensation practices.

Next Steps

• Continued vesting of the remaining 1,596,806 Restricted Stock Units in future quarterly installments.

Key Dates

Keywords

PLUS THERAPEUTICS, PSTV, Marc H. Hedrick, CEO, Director, Restricted Stock Units, RSU vesting, insider transaction, beneficial ownership, equity compensation